Correct Answer: C. Dantrolene
This clinical presentation is pathognomonic for malignant hyperthermia (MH): sudden-onset generalized muscle rigidity, rapid uncontrolled hyperthermia, tachycardia, and rising end-tidal CO₂ (reflecting hypermetabolism and muscle contraction) triggered by succinylcholine and volatile anesthetic (sevoflurane). The rising ETCO₂ despite controlled ventilation is the earliest and most sensitive sign of MH—it reflects uncontrolled muscle metabolism and rhabdomyolysis.
Dantrolene sodium is the only specific and definitive treatment for MH. It acts as a skeletal muscle relaxant by blocking calcium release from the sarcoplasmic reticulum via the ryanodine receptor, directly interrupting the hypermetabolic cascade. The immediate management protocol mandates: (1) stop all triggering agents immediately, (2) hyperventilate with 100% oxygen, (3) administer dantrolene IV 2.5 mg/kg, repeated every 5 minutes up to 10 mg/kg until signs of MH resolve (rigidity decreases, ETCO₂ normalizes, temperature stabilizes), and (4) active cooling measures. Early recognition and rapid dantrolene administration are life-saving—mortality has dropped from 80% (pre-dantrolene era) to <5% with prompt treatment. Dantrolene must be reconstituted immediately (each 20 mg vial requires 60 mL sterile water without bacteriostatic agents). In Indian operating theaters, dantrolene availability in emergency kits is now mandated by anesthesia guidelines.
Why the other options are wrong
A. Pancuronium — Pancuronium is a non-depolarizing neuromuscular blocker that would worsen rigidity and mask the underlying hypermetabolic crisis. It does not address the pathophysiology of MH (uncontrolled calcium release in muscle). Succinylcholine-induced rigidity requires cessation of triggering agents and dantrolene, not additional paralysis. This is a dangerous trap—students may confuse muscle relaxation with MH management. B. Diazepam — Diazepam is a benzodiazepine used for seizure prophylaxis and anxiety, not for the acute hypermetabolic crisis of MH. While it may be used adjunctively for post-MH complications (rhabdomyolysis-induced seizures), it has no direct effect on sarcoplasmic reticulum calcium release. It delays definitive treatment and does not prevent organ failure from uncontrolled muscle metabolism. D. Vecuronium — Vecuronium is a non-depolarizing neuromuscular blocker, similar to pancuronium. It does not treat MH and may mask clinical signs of the crisis. The rigidity in MH is due to uncontrolled intracellular calcium, not inadequate paralysis. Vecuronium would delay recognition and dantrolene administration, increasing mortality risk.
High-Yield Facts
- Malignant hyperthermia is triggered by succinylcholine and volatile anesthetics (sevoflurane, desflurane, isoflurane); safe agents are propofol, nitrous oxide, and non-depolarizing blockers.
- Rising ETCO₂ despite controlled ventilation is the earliest and most sensitive sign of MH—reflects hypermetabolism and rhabdomyolysis.
- Dantrolene 2.5 mg/kg IV is the only specific treatment; repeat every 5 minutes up to 10 mg/kg until rigidity resolves and ETCO₂ normalizes.
- Malignant hyperthermia is an autosomal dominant pharmacogenetic disorder affecting the ryanodine receptor (RYR1) or CACNA1S gene; 50% of offspring of affected patients are at risk.
- Post-MH complications include rhabdomyolysis, acute kidney injury (myoglobinuria), hyperkalemia, and disseminated intravascular coagulation; aggressive fluid resuscitation and urine alkalinization are essential.
- Dantrolene reconstitution requires sterile water without bacteriostatic agents; each 20 mg vial needs 60 mL water—preparation takes 5–10 minutes, so emergency kits must be pre-stocked.
Mnemonics
MH Triggers: SAVE CHOPS Succinylcholine, All volatile anesthetics (Sevoflurane, Desflurane, Isoflurane), Vapor anesthetics, Excitement/stress; Certain drugs (avoid); Heat; Oxygen (hyperoxia worsens); Pancuronium (avoid); Stress. Use to recall what triggers MH and what to avoid. MH Management: DANTROLENE FIRST Disconnect triggering agents, Airway/100% O₂, Normalize temp (active cooling), Treat with dantrolene 2.5 mg/kg IV, Repeat every 5 min, Observe ETCO₂ (should drop), Lab work (CK, K+, myoglobin), End-organ support (fluids, urine alkalization). Bedside mnemonic for OR crisis management.
NBE Trap
NBE may pair neuromuscular blockers (pancuronium, vecuronium) with MH to test whether students confuse muscle rigidity with inadequate paralysis. The trap is that additional paralysis masks the crisis and delays dantrolene administration—students must recognize that MH rigidity is metabolic, not mechanical.
Clinical Pearl
In Indian operating theaters, malignant hyperthermia is rare but catastrophic; many smaller centers lack dantrolene in emergency kits. The key bedside pearl: rising ETCO₂ in a rigid, febrile patient under anesthesia is MH until proven otherwise—stop all triggers, hyperventilate, and call for dantrolene immediately. Delayed recognition has killed patients in resource-limited settings.
_Reference: Harrison Ch. 387 (Anesthesia); KD Tripathi Ch. 10 (Neuromuscular Blockers & Dantrolene); Guyton & Hall Ch. 8 (Muscle Physiology & Calcium Regulation)_